1. In Vivo
  2. >>Leadership
  3. >>C-Suite Speaks

How Charl Van Zyl Is Reimagining Lundbeck

 
• By David Wild

Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.

Charl van Zyl
Charl van Zyl, CEO, Lundbeck (Søren Svendsen/Lundbeck)
Key Takeaways
  • Lundbeck's foundation ownership enables CEO van Zyl to prioritize long-term R&D investment in precision neurology despite looming patent cliffs.
  • The $2.6bn Longboard acquisition secures bexicaserin (patent protection until 2041) as a critical growth bridge beyond Rexulti's 2029 patent expiry.
  • Van Zyl has transformed Lundbeck's pipeline from predominantly early-stage assets to four Phase III programs by 2026, balancing current performance with future growth potential.

Amid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van...

“We are a company that’s revitalizing and reinventing ourselves,” van Zyl told In Vivo. “We’re building a company of the future, but one that is really dedicated to addressing severe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

More from Growth

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.